Categories
Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Warnings-33)

In this article we will discuss Durvalumab (Warnings-33)

In this article, we will discuss Durvalumab (Warnings-33). So, let’s get started.

  • Endocrine: Hypoparathyroidism
  • Other (hematologic/immune): Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.